More recently, a randomised placebo-controlled phase II trial on the highly selective ETAR blocker zibotentan showed a significant improvement in renal function at 52 weeks in SSc patients with chronic kidney disease in the zibotentan arm, without significant differences between the two groups regarding the expression of serum VCAM1—a candidate biomarker of SRC [90]. The gene discussed is EDNRA; the disease is systemic sclerosis.